MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis
MELT
1 other identifier
observational
138
1 country
73
Brief Summary
Desmopressin in treatment of nocturnal enuresis (bedwetting).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2011
73 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2011
CompletedFirst Submitted
Initial submission to the registry
June 7, 2011
CompletedFirst Posted
Study publicly available on registry
June 8, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2013
CompletedJune 12, 2013
June 1, 2013
1.8 years
June 7, 2011
June 11, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
Assessment of patient and parent satisfaction
3 months
Secondary Outcomes (4)
Number of wet nights
3 months
Assessment of drinking volume
3 months
Assessment of urine volume
3 months
Assessment of patient compliance
3 months
Study Arms (2)
Patients treated with orally disintegrating tablet
Patients treated with tablets
Eligibility Criteria
Patients with primary nocturnal enuresis
You may qualify if:
- Treatment of primary nocturnal enuresis within an overall therapeutical concept, eg, in cases of failure of other non-medicinal therapies or with indication of a medicinal therapy caused by nocturnal ADH deficiency
- The patients and their parents have been informed about the study and have given their written consent for participation.
You may not qualify if:
- The prescription of Minirin® tablets / Minirin® orally disintegrating tablet (fast dissolving desmopressin) is contraindicated
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ferring Pharmaceuticalslead
- Ferring Arzneimittel GmbHcollaborator
Study Sites (73)
Investigational Site
Bad Bergzaben, Germany
Investigational Site, Kaiserdamm 26
Berlin, Germany
Investigational Site, Mahlsdorfer Straße 39-40
Berlin, Germany
Investigational Site, Neckarstrasse 7
Berlin, Germany
Investigational Site, Potsdamer Chussee 80
Berlin, Germany
Investigational Site
Bingen, Germany
Investigational Site, Zossener Damm 42
Blankenfelde, Germany
Investigational Site , An der Ziegelei 8
Bonn, Germany
Investigational Site, Reichsstraße 51
Bonn, Germany
Investigational Site
Brackenheim, Germany
Investigational Site
Brunsbüttel, Germany
Investigational Site
Cologne, Germany
Investigational Site
Crailsheim, Germany
Investigational Site
Dresden, Germany
Investigational Site
Duisburg, Germany
Investigational Site, Suitberutsstraße 31
Düsseldorf, Germany
Investigational Site, Westfalenstraße 26
Düsseldorf, Germany
Investigational Site
Düsseldorf, Germany
Investigational Site
Erfurt, Germany
Investigational Site
Espelkamp, Germany
Investigational Site
Ettenheim, Germany
Investigational Site
Forchheim, Germany
Investigational Site
Frankfurt am Main, Germany
Investigational Site
Friedberg, Germany
Investigational Site
Fulda, Germany
Investigational Site
Gelsenkirchen, Germany
Investigational Site
Germering, Germany
Investigational Site
Gernsbach, Germany
Investigational Site
Gilching, Germany
Investigational Site
Görlitz, Germany
Investigational Site
Groß-Umstadt, Germany
Investigational Site
Großenhain, Germany
Investigational Site
Großröhrsdorf, Germany
Investigational Site
Hammelburg, Germany
Investigational Site
Hanover, Germany
Investigational Site
Harsewinkel-Greffen, Germany
Investigational Site
Homburg/Saar, Germany
Investigational Site
Hürth, Germany
Investigational Site
Hüttenberg, Germany
Investigational Site
Itzehoe, Germany
Investigational Site
Karlsruhe, Germany
Medical Faculty of University Clinic - Schwanenweg 20
Kiel, Germany
Investigational Site
Königswinter-Oberpl., Germany
Investigational Site, Neue Linner Straße 77
Krefeld, Germany
Investigational Site
Langerwehe, Germany
Investigational Site
Lehrte, Germany
Investigational Site
Lengerich, Germany
Investigational Site
Leverkusen-Schlebusch, Germany
Investigational Site
Minden, Germany
Investigational Site
Mönchengladbach, Germany
Investigational Site
Mutzschen, Germany
Investigational Site
Neu Wulmstorf, Germany
Investigational Site
Neumünster, Germany
Investigational Site
Oberhausen, Germany
Investigational Site
Oederan, Germany
Investigational Site, Waldstraße 43
Offenbach, Germany
Investigational Site
Offenbach, Germany
Investigational Site
Oldenburg, Germany
Investigational Site
Ottobrunn bei München, Germany
Investigational Site
Potsdam, Germany
Investigational Site
Rothenburg, Germany
Investigational Site
Rottweil, Germany
Investigational Site
Rüsselsheim am Main, Germany
Investigational Site
Schopfheim, Germany
Investigational Site
Schwabach, Germany
Investigational Site
Strausberg, Germany
Investigational Site
Traunstein, Germany
Investigational Site
Trittau, Germany
Investigational Site
Varel, Germany
Investigational Site
Wertheim am Main, Germany
Investigational Site
Wiefelstede, Germany
Investigational Site
Wilkau-Haßlau, Germany
Investigational Site
Wuppertal, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Development Support
Ferring Pharmaceuticals
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 7, 2011
First Posted
June 8, 2011
Study Start
June 1, 2011
Primary Completion
March 1, 2013
Study Completion
May 1, 2013
Last Updated
June 12, 2013
Record last verified: 2013-06